226 related articles for article (PubMed ID: 18300641)
21. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
22. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Mayer EL; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
[TBL] [Abstract][Full Text] [Related]
23. Lapatinib for advanced or metastatic breast cancer.
Opdam FL; Guchelaar HJ; Beijnen JH; Schellens JH
Oncologist; 2012; 17(4):536-42. PubMed ID: 22477724
[TBL] [Abstract][Full Text] [Related]
24. Denosumab an option for patients with bone metastasis from breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
[No Abstract] [Full Text] [Related]
25. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
[TBL] [Abstract][Full Text] [Related]
26. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
27. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
28. [Targeted therapies in breast cancer].
Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
[TBL] [Abstract][Full Text] [Related]
29. Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Clin Breast Cancer; 2005 Dec; 6(5):380-4. PubMed ID: 16381621
[No Abstract] [Full Text] [Related]
30. [New substances in the therapy of head and neck cancer].
Bogeschdorfer F; Gronau S; Riechelmann H
Laryngorhinootologie; 2006 Jul; 85(7):520-9; quiz 530-1. PubMed ID: 16791768
[TBL] [Abstract][Full Text] [Related]
31. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA
N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
[No Abstract] [Full Text] [Related]
33. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
34. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
35. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Morrow PK; Zambrana F; Esteva FJ
Breast Cancer Res; 2009; 11(4):207. PubMed ID: 19664181
[TBL] [Abstract][Full Text] [Related]
36. [Targeted therapy for locally advanced and/or metastatic bladder cancer].
Wallerand H; Robert G; Bernhard JC; Ravaud A; Ferrière JM
Prog Urol; 2008 Jul; 18(7):407-17. PubMed ID: 18602599
[TBL] [Abstract][Full Text] [Related]
37. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib: current status and future directions in breast cancer.
Moy B; Goss PE
Oncologist; 2006; 11(10):1047-57. PubMed ID: 17110623
[TBL] [Abstract][Full Text] [Related]
39. [Principles and method of action of targeted therapies].
Singer CF
Wien Med Wochenschr; 2010 Nov; 160(19-20):501-5. PubMed ID: 21080269
[TBL] [Abstract][Full Text] [Related]
40. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]